Prescient® specializes in decision support and product/portfolio strategy, helping you realize your molecules’ potential, shape strategic plans and make successful decisions. With us, your molecules have greater winning potential than the same science held by your competitors.

With eight global locations and 350+ experts, Prescient partners with the top biopharma companies, fastest-growing mid-caps and emerging biotechs, delivering clinical and commercial expertise.

Prescient is a portfolio company of Bridgepoint Development Capital (2021) and Baird Capital (2017).

Learn more